Quince Therapeutics relaunches as IRulya Therapeutics
Quince Therapeutics says it has relaunched under the name IRulya Therapeutics, focusing clinical development of LAM-001 targeting a key pathway in pulmonary disease.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
4 results loaded, newest first. End of these results.
Quince Therapeutics relaunches as IRulya Therapeutics
The company said it changed its name to IRulya Therapeutics effective Oct. 9 and will trade on Nasdaq under ticker IRLA from Oct. 12. It also announced new leadership appointments and said its cash balance should fund operations through the end of 2028.
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmon
Company common stock to trade on Nasdaq under the symbol “IRLA” effective October 12, 2026Key Management changes include new CEO, Brigette Roberts, M.D.; new CFO, John Militello, CPA; and new COO Keith R. Fandrick, Ph.D.Board strengthened with the addition of Catherine Bonuccelli, M.D., Leone Patte…